Antares Pharma to Present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care Conference
April 27 2017 - 7:00AM
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert
Apple, President and Chief Executive Officer, will present at the
Deutsche Bank Securities, Inc. 42nd Annual Health Care Conference
on Thursday, May 4, 2017 at 1:10 pm Eastern Time.
A live webcast of the presentation will be
available via the “Investor Information/Webcasts” page of the
Antares website, www.antarespharma.com. A replay of the webcast
will also be archived on Antares’ website for 90 days following the
presentation.
About Antares Pharma
Antares Pharma focuses on self-administered
parenteral pharmaceutical products. The Company’s product, OTREXUP®
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. The
Company’s product Sumatriptan Injection USP, is approved in the
U.S. for the acute treatment of migraine and cluster headache and
is distributed by Teva Pharmaceutical Industries, Ltd.
(Teva). Antares Pharma is also developing
QuickShot® Testosterone for testosterone replacement therapy and
has filed a New Drug Application with the Food and Drug
Administration. The Company's technology platforms include VIBEX®
disposable auto injectors, disposable multi-use pen injectors and
reusable needle-free injectors. Antares Pharma has license,
development and supply agreements with Teva that include VIBEX®
epinephrine, exenatide multi-dose pen, and teriparatide multi-dose
pen. Our reusable needle-free injector for use with human
growth hormone (hGH) is sold worldwide by Ferring B.V. The
Company is also working with AMAG Pharmaceuticals on a subcutaneous
method for administering Makena®, a progesterone product indicated
for use in lowering the risk of pre-term birth. For more
information, visit www.antarespharma.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: U.S. Food and Drug
Administration (“FDA”) approval of the QST NDA and future market
acceptance and revenue for QST; FDA approval of the sNDA submitted
AMAG Pharmaceuticals for an auto injector for Makena and future
market acceptance and revenue of the same; the outcome of the
pending patent litigation between Teva Pharmaceutical Industries,
Ltd. (Teva) and Eli Lilly and Company regarding the Teriparatide
multi-dose pen; FDA action with respect to Teva’s Abbreviated New
Drug Application (“ANDA”) for the Teriparatide multi-dose pen and
the timing and approval, if any, by the FDA of the same; Teva’s
ability to adequately and timely respond to the Complete Response
Letter received from the FDA for the VIBEX® epinephrine pen ANDA
and approval by the FDA of the same, the timing and therapeutic
equivalence rating thereof, and any future purchase orders and
revenue pre or post FDA approval; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan Injection USP and the amount of
revenue from the same; FDA action with respect to Teva’s ANDA filed
for the Exenatide pen and future revenue from the same; continued
growth of prescriptions and sales of OTREXUP®; ; the timing
and results of research projects, clinical trials, and
product candidates in development; actions by the FDA or other
regulatory agencies with the respect to the Company’s products or
product candidates of its partners; continued growth in product,
development, licensing and royalty revenue; the Company’s ability
to obtain financial and other resources for its research,
development, clinical, and commercial activities and other
statements regarding matters that are not historical facts, and
involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2016, and in the Company's other periodic
reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release. All forward-looking statements are based on information
currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contact:
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024